| CPC A61K 31/688 (2013.01) [A61K 9/0053 (2013.01); A61K 9/48 (2013.01); A61K 31/685 (2013.01); A61K 35/57 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61K 2236/00 (2013.01)] | 1 Claim | 
| 
               1. A method of treating leukemia in a human patient in need thereof comprising administering to said patient a pharmaceutical composition consisting of a plurality of phosphatidylcholine compounds and one or more pharmaceutically acceptable diluents, excipients, and/or carriers: wherein said plurality of phosphatidylcholine compounds comprise 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine and one or more phosphatidylcholines selected from the group consisting of: 
            1-palmitoleoyl-2-linoleoyl-sn-glycero-3-phosphocholine, 
                1-palmitoyl-2-α-linolenoyl-sn-glycero-3-phosphocholine, 
                1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine, 
                1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine, 
                1-α-linolenoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine, 
                1-palmitoleoyl-2-oleoyl-sn-glycero-3-phosphocholine, 
                1-palmitoleoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine, 
                1-palmitoyl-2-osbodnoyl-sn-glycero-3-phosphocholine, 
                1-oleoyl-2-arachidonoyl-sn-glycero-3-phosphocholine, 
                1-oleoyl-2-linoleoyl-sn-glycero-3-phosphocholine, 
                1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine, 
                1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, 
                1-oleoyl-2-docosahexenoyl-sn-glycero-3-phosphocholine, 
                1,2-dioleoyl-sn-glycero-3-phosphocholine, 
                1-stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine, and 
                1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine. 
               |